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Background: Recent work has shown that the gap junction protein connexin43 (Cx43) is upregulated in cells of
the joint during osteoarthritis (OA). Here we examined if the OA-associated increase in Cx43 expression impacts the
function of synovial fibroblasts by contributing to the production of catabolic and inflammatory factors that exacerbate
joint destruction in arthritic disease.
Methods: Using rabbit and human synovial fibroblast cell lines, we examined the effects of Cx43 overexpression and
Cx43 siRNA-mediated knockdown on the gene expression of OA-associated matrix metalloproteinases (MMP1 and
MMP13), aggrecanases (ADAMTS4 and ADAMTS5), and inflammatory factors (IL1, IL6 and PTGS2) by quantitative real
time RT-PCR. We examined collagenase activity in conditioned media of cultured synovial cells following Cx43
overexpression. Lastly, we assessed the interplay between Cx43 and the NFκB cascade by western blotting and gene
expression studies.
Results: Increasing Cx43 expression enhanced the gene expression of MMP1, MMP13, ADAMTS4, ADAMTS5, IL1, IL6 and
PTGS2 and increased the secretion of collagenases into conditioned media of cultured synovial fibroblasts. Conversely,
knockdown of Cx43 decreased expression of many of these catabolic and inflammatory genes. Modulation of Cx43
expression altered the phosphorylation of the NFκB subunit, p65, and inhibition of NFκB with chemical inhibitors
blocked the effects of increased Cx43 expression on the mRNA levels of a subset of these catabolic and inflammatory
genes.
Conclusions: Increasing or decreasing Cx43 expression alone was sufficient to alter the levels of catabolic and
inflammatory genes expressed by synovial cells. The NFκB cascade mediated the effect of Cx43 on the expression of a
subset of these OA-associated genes. As such, Cx43 may be involved in joint pathology during OA, and targeting Cx43
expression or function may be a viable therapeutic strategy to attenuate the catabolic and inflammatory environment
of the joint during OA.
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OA is a progressive degenerative joint disease caused by
wear and tear on the articular surface. OA is thought to
be a total joint disease, involving contribution from the ar-
ticular chondrocytes, sub-chondral bone and synovium
[1]. Articular chondrocytes are responsible for producing
and maintaining the articular cartilage extracellular matrix* Correspondence: jstai002@umaryland.edu
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unless otherwise stated.that provides a smooth surface for low friction joint move-
ment and “shock absorbing” properties. The synovial cells
form a thin lining within the fibrous joint capsule sur-
rounding the joint space. The synovium is composed
of synovial fibroblasts and synovial macrophages. The
physiologic function of the synovial fibroblasts is to
produce a synovial fluid rich in hyaluronan and superfi-
cial zone protein/lubricin that lubricates the joint to fa-
cilitate low friction movement. While the etiology of
OA is complex, biomechanical and biological factors,
such as mechanical strain and inflammatory cytokinesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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catabolic factors in the joint, ultimately leading to the
destruction of the articular cartilage. Specifically, syn-
ovial cells and articular chondrocytes produce catabolic
factors, such as matrix metalloproteinases (e.g., MMP-1
and −13), aggrecanases (e.g., ADAMTS-4 and −5), and
pro-inflammatory factors/cytokines (e.g., IL-1, IL-6,
TNFα, nitric oxide, prostaglandin E2 (PGE2)) that con-
tribute to joint destruction in OA [2-5]. Ultimately, the
destruction of articular cartilage can affect joint mobil-
ity, leading to severe joint stiffness and pain. Determin-
ing the precise contribution and the dynamic interplay
between the joint tissue during disease onset and pro-
gression is critical to understanding OA and for devel-
oping interventions.
One means by which cells and tissues coordinate func-
tion is via cell-to-cell communication through gap junc-
tion proteins. Gap junctions are made up of connexin
monomers that assemble to form a hemichannel. Gap
junctions are formed when hemichannels on the plasma
membrane of adjacent cells dock to create a transcellular
channel. The resultant gap junction channel permits the
direct exchange of second messengers, metabolites, ions
and other small molecules (<1.0 kDa) among coupled
cells. Gap junctions aggregate into large gap junction
plaques at the interface of adjacent cells, forming a func-
tional syncytium for the coordinated function of a tissue.
Notably, the majority of cells in the joint express the gap
junction protein Cx43, including synovial fibroblasts, ar-
ticular chondrocytes and osteoblasts, as well as cells of
the meniscus and ligaments [6-13]. In fact, intercellular
gap junctional communication has been demonstrated
among chondrocytes of the superficial layer of articular
cartilage in vivo [14]. Ex vivo chondrocytes in cartilage
explants have been shown to form functional gap junc-
tion networks [15].
In addition to its role in direct gap junctional commu-
nication, Cx43 can also form hemichannels that commu-
nicate signals directly to the extracellular space [16,17].
In the cells of bone and cartilage, hemichannels have
been implicated in signaling mechanical load responses
[18,19] and are thought to function by serving as con-
duits for the release of ATP or PGE2 into the extracellu-
lar milieu following mechanical strain [20]. Regardless of
the mode of action (hemichannel or gap junction chan-
nel), the relative expression of Cx43 alone impacts signal
transduction cascades, gene expression and cell function,
at least in bone cells [21].
Several lines of evidence indicate a role for Cx43 in
OA. Synovial biopsies from patients with OA have an in-
crease in Cx43 expression and an increase in the size
and number of gap junction plaques [22]. Furthermore,
ex vivo analysis of synovial biopsies of patients with OA
revealed that pharmacologic inhibition of Cx43 functionreduced the basal and IL-1β-stimulated production of
collagenase activity [22,23]. We have shown that treat-
ment of HIG82 rabbit synoviocytes in culture with IL-1β,
a contributor to OA, markedly increases the expression of
Cx43 and increased gap junctional intercellular communi-
cation among these cells [24]. Similarly, it has been re-
ported that IL-1β enhances Cx43 expression in articular
chondrocytes [25,26]. Further, the density of Cx43 posi-
tive cells is markedly enhanced in the superficial zone
of osteoarthritic articular cartilage [8]. A more than 40-
fold increase in Cx43 protein expression was noted in
the articular chondrocytes of OA cartilage compared to
healthy controls, with the biggest differences in Cx43
accumulation in the superficial and mid zone of the ar-
ticular cartilage [13]. High levels of Cx43 staining were
seen early in OA and was noted in areas of healthy as
well as degraded cartilage, suggesting that altered Cx43
expression may be an early phenotypic change in these
cells prior to OA-associated cartilage destruction [13].
However, the mechanism of Cx43 upregulation in OA
and the consequence of enhanced Cx43 expression in
these cells within the osteoarthritic joint are not yet
known. Among osteoblasts, we and others have shown
that Cx43 impacts the expression of numerous genes
by modulating several signal transduction cascades
[21,27,28]. In the present study, we examine how in-
creasing Cx43 levels in human and rabbit synovial fi-
broblasts affect the expression of several OA-associated
catabolic and inflammatory genes.
Methods
Cell culture and transfection
The HIG82 rabbit synovial fibroblast-like cell line (ATCC)
was cultured as described previously [24]. The SW982 hu-
man synovial sarcoma cell line (ATCC) was cultured in
Leibovitz’s L-15 medium and maintained in a 37°C incu-
bator with atmospheric CO2. HIG82 cells were transfected
with Lipofectamine 2000 (Life Technologies), as we have
published [24]. SW982 cells were transfected with calcium
phosphate co-precipitation, as described [29] or with
Lipofectamine 2000. The pSFFV-Cx43 construct, which
contains the full-length rat Cx43 open reading frame
cloned into the EcoR1 site of the pSFFV-neo plasmid [30],
was provided by Dr. Thomas Steinberg (Washington
University, St Louis, MO). The pSFFV-neo empty vec-
tor [31] was provided by Dr. Gabriel Nunez (University
of Michigan, Ann Arbor, MI). All plasmid DNA was
prepared using PureYield endotoxin free plasmid maxi
prep kit (Promega). Non-targeting and human GJA1
targeting-siRNA Smartpool constructs were purchased
from Dharmacon and were used at 25pmol/cm2. MG132,
dissolved in DMSO, was used at 50 μM. The IKK-2 in-
hibitor IV (5-(p-Fluorophenyl)-2-ureido] thiophene-3-
carboxamide) was dissolved in DMSO and used at 10 μM.
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DMSO as a vehicle control for 4–5 hours (real time
PCR) or 1 hour (immunoblots) prior to harvest. IL-1β
was used at 100 ng/ml for 20 minutes to stimulate the
phosphorylation of the p65 subunit of NFκB, following
pretreatment of the cells with MG132 inhibitor or
DMSO control.RNA isolation and quantitative RT-PCR
Forty-eight hours post transfection, cells were har-
vested for RNA extraction using Directzol RNA mini-
prep (Zymo). RNA (1 μg) was reverse transcribed with
either iScript (BioRad) or RevertAid (Fermentas) re-
verse transcription master mix, according to the manu-
facturers directions. Quantitative real time PCR was
carried out using the SYBR green method, as described
previously [24]. For rabbit synovial cell samples, relative
gene expression was normalized to 18SrRNA data. For
human synovial cell samples, the relative gene expres-
sion was simultaneously normalized to the expression
of three house keeping genes, RPL13, HPRT and GAPDH
using the GeNorm v3.5 Software (Ghent University
Hospital Ghent, Belgium), as described previously [32].
All data were also normalized to the expression levels
in the empty vector control. The primer sets used for
PCR are shown in Table 1.Table 1 PCR primers
Target Species Primer 1
MMP1 Human TTT GAT GGA CCT GGA GG
MMP13 Human ATT AAG GAG CAT GGC GA
ADAMTS4 Human CTA TGG GCA CTG TCT CTT
ADAMTS5 Human AAT AAC CCT GCT CCC AG
IL1 Human CGA ATC TCC GAC CAC CA
IL6 Human TGT AGC CGC CCC ACA CA
PTSG2 Human CAG CAC TTC ACG CAT CA
HPRT Human TGA CAC TGG CAA AAC AA
GAPDH Human CCC ACT CCT CCA CCT TTG
RPL13 Human AGC CTT CGC TAG TCT CCG
Gja1 Rat CGA TTT CCC CGA CGA CA
MMP1 Rabbit TGT ATC GTG TTG CAG CTC
MMP13 Rabbit AGT AGT TCC AAA GGC TA
ADAMTS4 Rabbit ACT GGG TTC CGC GCT AC
ADAMTS5 Rabbit CCT GGG CCC CGA AGA AC
IL1B Rabbit TCC AGA CGA GGG CAT CC
IL6 Rabbit GAA CCT GCA GCA GAA AA
PTSG2 Rabbit GCT GTG GGC CAG GAA GT
18SrRNA multi CAT TAA ATC AGT TAT GGT
Primer sets for quantitative real time RT-PCR.MMP activity assay
MMP activity was measured in conditioned media col-
lected from cultured cells 72 hours post-transfection,
using the EnzChek Gelatinase/Collagenase Assay kit
(Life Technologies), according to manufacturer’s direc-
tions. Briefly, conditioned media (100 μl) was added to the
fluorescently tagged gelatin substrate (100 μl, 100 μg/ml
final concentration in the supplied 1X reaction buffer).
The samples were incubated at room temperature for 2–4
hours and at room temperature, followed by analysis
of fluorescent intensity (excitation, 495 nm, emission
515 nm) on a fluorescent microplate reader. Data are dis-
played relative to the empty vector transfected control.
Western blotting
Western blotting of whole cell extracts isolated from
cells in culture was done as previously described [33].
Briefly, whole cell extracts were prepared from cultured
cells 72 hours post transfection using a modified RIPA
buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl.
10 mM sodium pyrophosphate, 10 mM sodium fluoride,
10 mM β-glycerophosphate, 1 mM EGTA, 1 mM EDTA,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1X
HALT protease and phosphatase inhibitor cocktail
(Thermo Scientific). Insoluble material was pelleted, and
equal concentrations of the supernatants were electro-
phoresed on 10% SDS-PAGE gels and transferred toPrimer 2
A AAT C TGA GCA TCC CCT CCA ATA CC
C TTC T CCC AGG AGG AAA AGC ATG AG
AGA CAA AC CAC TGG CGG TCA GCA TCA
A AAC A GCG GTA GAT GGC CCT CTT C
C TAC TCC ATG GCC ACA ACA ACT GA
GGA TGT ACC GAA TTT GTT TGT CAA
G TTT T CCA GCC CGT TGG TGA AAG
T GCA GCT TGC GAC CTT GAC CAT CT
AC CAT ACC AGG AAA TGA GCT TGA CAA
TAT G TGG CTC TTT TTG CCC GTA TG
A TGG CTA ATG GCT GGA GTT CAT
ATG A AAA GCC CCA ATA TCA GTA GAA TGG
C AAC TTG TTT GGA GTG GTC AAG CCC TAA GGA
A CCT GGC AGG TGA GTT TGC A
CGA ACG TCA AGT TGC ATT GC
A TGC CGG AAG CTC TTG TTG TA
A CCA GGC CGC GCA GGA TGA
G GCC AGA TTG TGG CAT ACA TCA
TCC TTT GG TCG GCA TGT ATT AGC TCT AGA ATT ACC
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blocked in 5% non- fat dry milk, probed with the indicated
primary antibodies overnight, and detected with the ap-
propriate horseradish peroxidase–conjugated antibodies
and enhanced chemiluminescence detection reagents
(BioRad). Blots were acquired and analyzed using an
EpiChem gel documentation system (UVP Bioimaging
Systems). The rabbit anti-connexin43 antibody was
purchased from Sigma. The rabbit anti-phospho-NFκB
p65 (Ser536) was purchased from Cell Signaling Technol-
ogy. The mouse anti-GAPDH antibody was purchased
from Millipore. Relative expression was calculated using
ImageJ to quantitate band intensity. Data are relative to
the expression of GAPDH.Statistical analysis
Experiments were repeated a minimum of 3 times with
triplicate wells, unless indicated otherwise. Graphs show
averages with error bars indicating standard deviations.
Samples were compared by an ANOVA for unpaired
samples with a Dunnet’s post-hoc test or a t-test, as ap-
propriate, using Prism 6 software. A p-value <0.05 was
used as a threshold for statistical significance.Figure 1 Transfection with a Cx43 expression construct increased the
MMP activity in HIG82 synovial fibroblasts in vitro. By quantitative real
with increasing concentrations of a rat Cx43 expressing plasmid (pSFFV-Cx43)
as well as the rat Gja1 transgene (please note, these primers do not detect th
the aggrecanases, ADAMTS4 and ADAMTS5, were increased by the overexpres
media from Cx43 transfected HIG82 cells was increased nearly 2-fold rela
kept constant in all wells by the inclusion of the appropriate amount of an em
Asterisks indicate p-value < 0.05 relative to the empty vector (0 μg) control.Results
Quantitative real time RT-PCR showed that transient
transfection with rat Cx43 (pSFFV-rCx43) in rabbit syn-
ovial fibroblasts (HIG82 cells) was sufficient to induce the
gene expression of several catabolic factors associated
with OA, including the matrix metalloproteinases, MMP1
and MMP13, and the aggrecanases, ADAMTS4 and
ADAMTS5, compared to cells transfected with an empty
vector (pSFFV-neo) (Figure 1A-B). The expression of
these factors dose-dependently increased with the levels of
the rat Gja1 (Cx43) transgene expression. Further, trans-
fection with a Cx43 expressing plasmid in HIG82 cells
increased matrix metalloproteinase activity in the condi-
tioned media of these rabbit synovial cells as determined
by a fluorometric MMP activity assay (Figure 1C). Simi-
larly, transfection with Cx43 dose-dependently increased
the gene expression of the OA-associated inflammatory
mediators, IL1B, IL6 and PTGS2 (COX2) in HIG82 cells
(Figure 2).
Next, we wanted to show that disruption of Cx43 ex-
pression or function would reduce expression of these
genes. However, attempts to knockdown Cx43 expression
with siRNAs were unsuccessful in these rabbit synovial
cells. Meanwhile, pharmacologic inhibition of gap junctionexpression of MMP1, MMP13, ADAMTS4, ADAMTS5 mRNA and
time RT-PCR, transient transfection of HIG82 rabbit synovial fibroblasts
dose dependently increased the gene expression of (A) MMP1, MMP13
e endogenous rabbit Cx43). N = 3. (B) Likewise, the gene expression of
sion of Cx43. N = 3. (C) Matrix metalloproteinase activity in conditioned
tive to cells transfected with an empty vector. N = 3. Total DNA was
pty vector (pSFFV-neo). Data are shown as means ± standard deviations.
Figure 2 Transfection with a Cx43 expression construct increased the expression of IL1B, IL6 and PTGS2 mRNA in HIG82 synovial
fibroblasts in vitro. By quantitative real time RT-PCR, transient transfection of HIG82 rabbit synovial fibroblasts with increasing concentrations of
a rat Cx43 expressing plasmid (pSFFV-Cx43) dose dependently increased the gene expression of IL1B, IL6 and PTGS2. N = 3. Total DNA was kept
constant in all wells by the inclusion of the appropriate amount of an empty vector (pSFFV-neo). Data are shown as means ± standard deviations.
Asterisks indicate p-value < 0.05 relative to the empty vector (0 μg) control.
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reducing gene expression and matrix metalloproteinase
production in HIG82 cells, but issues of cell viability/cell
health in the presence of these inhibitors made interpret-
ation difficult (data not shown). As a result, we instead ex-
amined the effects of Cx43 on the function of human
synovial fibroblast cell line (SW982) in which we could ef-
fectively knockdown Cx43 gene expression with commer-
cial siRNAs. SW982 cells are derived from a humanFigure 3 Transfection of human synovial fibroblast-like cells with a Cx4
catabolic and inflammatory genes. By quantitative real time RT-PCR, trans
rat Cx43 expressing plasmid (pSFFV-Cx43) significantly increased the gene
ADAMTS4 and ADAMTS5 and the inflammatory cytokine genes (B) IL1, IL6
Asterisks indicate p-value < 0.05 relative to the empty vector control. (C)
Cx43 expression in pSFFV-Cx43 transfected cells relative to cells transfectesynovial sarcoma and behave similarly to human syn-
ovial fibroblasts including their ability to produce in-
flammatory and catabolic factors, including IL-1, IL-6,
Cox2/PTGS2, iNOS/NOS2, TGFβ, MMP-1, −2, −3 and
−13 and ADAMTS-4, both basally and at markedly in-
creased levels following treatment with IL-1β [34,35].
As was noted for HIG82 cells, increasing Cx43 protein
expression (Cx43 protein levels were typically 1.5-2.5
fold higher than empty vector transfected controls as3 expression construct increased the expression of OA-associated
ient transfection of SW982 human synovial fibroblast-like cells with a
expression of the OA-associated catabolic genes (A) MMP1, MMP13,
and PTGS2. N = 3. Data are shown as means ± standard deviations.
Immunoblotting of transfected SW982 cells showed an increase in
d with an empty vector (EV). GAPDH was used as a load control.
Figure 4 Cx43 Knockdown in human synovial fibroblast-like cells reduced the expression of OA-associated catabolic and inflammatory
genes. By quantitative real time RT-PCR, transient transfection of SW982 human synovial fibroblast-like cells with GJA1 targeting siRNAs (GJA1)
reduced the gene expression of some OA-associated (A) catabolic genes and (B) inflammatory genes relative to a scrambled siRNA control (SCR)
N = 3. Data are shown as means ± standard deviations. Asterisks indicate p-value < 0.05 relative to the empty vector control. (C) Immunoblotting
of transfected SW982 cells confirmed a decrease in Cx43 expression in GJA1 siRNA transfected cells relative to cells transfected with a scrambled
control siRNA (SCR). GAPDH was used as a load control.
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ovial cells by transient transfection enhanced the gene
expression of MMP1, MMP13, ADAMTS4, ADAMTS5,
IL1, IL6 and PTGS2 compared to cells transfected with
an empty vector (Figure 3). Conversely, when Cx43 ex-
pression was knocked down in SW982 cells with siRNA
directed against GJA1 (the gene encoding Cx43), the
gene expression of MMP13, ADAMTS4, IL6 and PTGS2
were significantly reduced relative to cells transfected
with a scrambled siRNA control (Figure 4A). The gene
expression of MMP1, ADAMTS5 and IL1 were also
mildly reduced but did not reach statistical significance.Figure 5 Modulation of Cx43 expression affected the NFκB pathway.
cells showed that (A) overexpression of Cx43 enhanced the abundance of ph
Cx43 expression had the opposing effect. GAPDH was used as a load control.Next, we examined the underlying molecular mecha-
nisms by which Cx43 may impact expression of the genes.
Because many of the Cx43-sensitive genes that we tested
are direct targets of the canonical NFκB cascade, we eval-
uated the influence of Cx43 on this pathway. Examination
of the phosphorylation of the p65 subunit of NFκB by
western blotting revealed that increasing Cx43 expression
enhanced phospho-p65 levels, while Cx43 knockdown di-
minished phospho-p65 levels (Figure 5). Importantly, in-
hibition of the NFκB pathway with MG132 blocked the
impact of Cx43 overexpression on the production of a
subset of these OA-associated catabolic and inflammatoryImmunoblots from whole cell extracts of transiently transfected SW982
ospho-p65 (RelA) subunit of the NFκB complex while (B) knockdown of
Figure 6 (See legend on next page.)
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Figure 6 Inhibition of the NFκB pathway prevented the ability of Cx43 overexpression to enhance the expression of some OA-associated
catabolic and inflammatory genes. By quantitative real time RT-PCR, transient transfection of SW982 human synovial fibroblast-like cells with a rat
Cx43 expressing plasmid (pSFFV-Cx43) significantly increased the gene expression of the OA-associated catabolic and inflammatory genes (A) MMP1,
ADAMTS5, IL1 and PTGS2. This effect of Cx43 on the expression of these genes was abrogated by inhibition of the NFκB pathway with MG132 (50 μM,
5 hours). N = 3. Data are shown as means ± standard deviations. Asterisks indicate p-value < 0.05 relative to the corresponding vehicle treated control.
(B) Immunoblots showed that Cx43 overexpression increased the abundance of phospho-p65 NFκB, an effect that could be inhibited by exposure to
MG132 (50 μM, 1 hours). GAPDH was used as a load control. This blot is from a single gel and single exposure but is from non-contiguous lanes. The
irrelevant lanes have been digitally removed. (C) Immunoblot with anti-phospho-p65 NFκB antibodies confirms the effectiveness of MG132 to inhibit
the NFκB pathway when the pathway is stimulated by IL1β (100 ng/ml, 20 minutes). (D) Treatment with the NFκB pathway inhibitor (IKK2-inhibitor IV,
10 μM, 4 hours) reduced the Cx43-dependent expression of several OA-associated genes, as determined by quantitative real time RT-PCR. N = 3. Data
are shown as means ± standard deviations. Asterisks indicate p-value < 0.05 relative to the corresponding vehicle treated control.
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reduced the amount of phospho-p65 in Cx43-expressing
SW982 cells (Figure 6A-C). Similarly, use of the NFκB
pathway inhibitor, IKK-2 inhibitor IV, blocked the effects
of Cx43 overexpression of several OA-associated genes
(Figure 6D).Discussion
In this manuscript, we showed that increasing Cx43
levels in synovial cells is sufficient to enhance the ex-
pression of OA-associated catabolic and inflammatory
genes in both rabbit and human synovial fibroblasts.
Given that Cx43 is upregulated in both articular chon-
drocytes and synovial cells in OA [13,22], as well as the
present data and the data of others suggesting that Cx43
can influence the expression of genes associated with
OA [22,23], it is important to consider that Cx43 could
contribute to the subsequent pathology of the joint and
may be a therapeutic target to treat OA. Of course, it
must be acknowledged that this work is done in cell
lines and needs to be confirmed in vivo. Promisingly, in
a rat model of collagen induced rheumatoid arthritis,
silencing Cx43 expression with siRNA diminished both in-
flammation and ankle joint destruction [36]. In addition,
ex vivo Cx43 siRNA reduced the expression of inflamma-
tory cytokines in rat fibroblast-like synovial cells from
these animals [36]. These findings are consistent with our
data, which also show that knockdown of Cx43 can re-
duce the expression of a subset of OA-associated catabolic
genes and inflammatory genes. In fact, in our systems all
of the tested OA-associated genes were diminished by
transfection of the cells with GJA1-targeted siRNAs, even
if only a subset reached statistical significance. Import-
antly, our model of Cx43 overexpression consistently pro-
duces a 1.5-2 fold increase in Cx43 protein in the human
synoviocytes. This is consistent with the level of expres-
sion observed in synovial biopsies from OA patients rela-
tive to non-OA patients [22] and substantially less than
the ~30-fold increase in Cx43 protein observed in articu-
lar chondrocytes from patients with OA [13].Little is known regarding the molecular mechanisms by
which alterations of Cx43 could affect gene expression in
synovial cells. Our previous work in bone cells has shown
that numerous signal transduction cascades, such as ERK
and Protein Kinase C delta (PKCδ), can influence gene ex-
pression downstream of Cx43 [32,33,37]. Others have
shown in bone cells that Cx43 can regulate other path-
ways, including β-catenin expression [38,39] and βarres-
tin/cAMP signaling [40]. Less is known regarding the role
of Cx43 and downstream signaling in the synovium or ar-
ticular cartilage, beyond the propagation of Ca2+ waves
[41,42]. In the present study, we showed that Cx43 regu-
lates the NFκB signaling pathway in synovial fibroblasts,
with gain of Cx43 increasing and loss of Cx43 decreasing
signaling through this pathway. It is not surprising that
NFκB is a target influencing the expression of a subset of
these OA-associated genes, as this pathway is intimately
associated with OA and has been a target of therapeutic
intervention in arthritic disease [43,44]. Rather, what is
novel is that this is the first study that we are aware of
that shows that Cx43 regulated the expression of OA-
associated genes and the activity of the NFκB pathway.
Our western blotting data clearly showed modulation
of phosphorylation of p65 RelA as a result of increasing
or decreasing Cx43 in these cells. Further, two pharma-
cologic inhibitors of the NFκB pathway markedly re-
duced the effect of Cx43 on gene expression. Of course,
studying NFκB pathway signaling in the context of a
synovial sarcoma cell line (SW982) is a limitation as al-
tered NFκB signaling is a hallmark of these cells. How-
ever, we have observed a similar regulation of NFκB
signaling by Cx43 in other cell types as well (data not
shown). Even if these synovial sarcoma cells have ele-
vated basal NFκB, there is little reason to suspect that
the mechanisms by which Cx43 modulates this pathway
are not conserved among primary cells. Nonetheless,
future experiments will examine the regulation of these
synovial cell function in primary cells in culture or in vivo.
Importantly, as has been observed in osteoblasts and oste-
ocytes, it is unlikely that NFκB is the only signaling
pathway affected downstream of Cx43 in synovial cells.
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cules and can affect signaling by modulating cell-to-cell
diffusion of second messengers, as well as by structural
interactions [21,45-47]. Future studies will look at sig-
nal transduction cascades such as PKCδ, which is in-
volved in Cx43-dependent signaling in bone cells where
it converges on Runx2 [48] and has also been implicated
in OA pathogenesis and the expression of MMP13 via
Runx2 [49,50].
Importantly, we do not know if this same Cx43-
dependent effect is also present in articular chondro-
cytes. While numerous studies have shown that Cx43 is
expressed in articular chondrocytes, how Cx43 func-
tions in these cells is uncertain. Cx43 can function as
unopposed hemichannels in articular cartilage [8,51,52],
and the mechanisms that govern signal transduction in
the context of classic cell-to-cell communication through
gap junctions are likely different than with hemichannels
[53]. In addition, studies have shown functional cell-to-
cell communication via classic gap junctions between
articular chondrocytes in the superficial layer, as well
as extensive gap junctional coupling among articular
chondrocytes in a network that is analogous to the
osteocytic canalicular network found in bone [13-15].
Future studies will investigate the role of Cx43 in ar-
ticular chondrocyte function.
Interestingly, this is the first study to show that Cx43
abundance can impact the expression of PTGS2, the gene
encoding COX2, an enzyme involved in the production of
PGE2. Studies have shown a relationship between Cx43
and PGE2, particularly in response to mechanical load in
osteocytes and articular chondrocytes, with mechanical
stimulation increasing Cx43 expression and subsequently
PGE2 release [52,54,55]. Those studies have focused to
some extent on the Cx43-dependent release of PGE2 from
cells. If Cx43 can also influence the transcription of
PTGS2 and the synthesis of PGE2 in those systems, as it
does in synovial cells, it should also be considered that the
increase in PGE2 observed in osteocytes and articular
chondrocytes following mechanical stimulation may be
secondary to or in addition to the transcriptional control
of PTGS2 by Cx43. Future studies will need to clarify this
issue.
Combined with our previous work and the work of
others showing increases in Cx43 in synovial cells the
OA joint, the present data support a model in which
OA-associated changes in the joint (e.g., inflammation,
altered mechanical load) can increase Cx43 expres-
sion. Further, Cx43 upregulation is sufficient to lead to
the production of additional catabolic and inflamma-
tory factors. The result is a vicious cycle that culmi-
nates in joint destruction. Accordingly, it is reasonable
to predict that targeting Cx43 or at least the subset
of signal transduction cascades affected by Cx43abundance could offer therapeutic benefit in the treat-
ment of OA.
Conclusions
Increased levels of Cx43 are observed in synovial biopsies
from patients with OA. Accordingly, we examined the
impact of increased Cx43 on the expression of OA-
associated genes. Increasing the levels of Cx43 is sufficient
to drive the expression of catabolic and inflammatory
genes by synovial cells, while knockdown of Cx43 could
decrease the expression of these genes. The NFκB cascade
mediates the effect of Cx43 on the expression of a subset
of these OA-associated genes. As such, targeting Cx43 ex-
pression or function may be a viable therapeutic strategy
to attenuate the catabolic and inflammatory environment
of the joint during OA.
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